How should viral conjunctivitis (pink eye) be managed?

Management of Viral Conjunctivitis

Most viral conjunctivitis is self-limited and requires only supportive care with strict hygiene measures to prevent transmission—avoid indiscriminate use of antibiotics or corticosteroids in uncomplicated cases 1.

Initial Management Approach

For Presumed Adenoviral Conjunctivitis (Most Common)

Supportive care is the cornerstone:

• Artificial tears for symptomatic relief
• Cold compresses to reduce discomfort
• Topical antihistamines may help with irritation
• Strict hand hygiene is essential—this is a highly contagious condition that spreads via fomites 2, 3

Key clinical pitfall: Viral conjunctivitis will not respond to antibacterial agents, and indiscriminate antibiotic use should be avoided 1. Most cases resolve within 2-3 weeks without specific treatment.

Follow-Up Strategy

Patients NOT on corticosteroids: Return only if symptoms of red eye, pain, or decreased vision persist beyond 2-3 weeks 1.

Patients with severe disease or complications: Re-evaluate within 1 week if corneal epithelial ulceration or membranous conjunctivitis is present 1.

Management of Subepithelial Infiltrates (SEIs)

SEIs typically develop 1 or more weeks after onset and represent a key complication affecting vision quality.

Treatment algorithm based on severity:

• Mild cases with no visual symptoms: Observation only 1

• Cases with blurring, photophobia, or decreased vision:

  • Topical corticosteroids at minimum effective dose (fluorometholone or loteprednol preferred due to lower risk of IOP elevation and cataract formation) 1
  • Alternative: Cyclosporine drops 0.05% to 1% have been found helpful in reducing SEIs 1
  • Taper slowly to minimum effective dose once controlled
  • Monitor IOP and perform slit-lamp examination regularly 1

Critical monitoring for steroid users: Regular follow-up with visual acuity, IOP measurement, and pupillary dilation to evaluate for glaucoma and cataract 1.

Herpes Simplex Virus (HSV) Conjunctivitis

This requires specific antiviral treatment—do not use corticosteroids as they potentiate HSV epithelial infections 1.

Treatment Options:

Topical antivirals:

• Ganciclovir 0.15% gel: 3-5 times daily (less toxic to ocular surface) 1
• Trifluridine 1% solution: 5-8 times daily (causes epithelial toxicity if used >2 weeks) 1

Oral antivirals (often combined with topical for better efficacy):

• Acyclovir: 200-400 mg five times daily
• Valacyclovir: 500 mg 2-3 times daily
• Famciclovir: 250 mg twice daily 1

Critical point: Oral antivirals alone may not prevent progression of HSV blepharoconjunctivitis—addition of topical antiviral is more effective 1.

Neonates: Require immediate pediatrician consultation as systemic HSV infection is life-threatening 1.

Follow-up: Within 1 week with visual acuity and slit-lamp examination 1.

Varicella Zoster Virus (VZV) Conjunctivitis

For persistent or recalcitrant disease in immunocompetent patients, use oral antivirals:

• Acyclovir: 800 mg five times daily for 7 days
• Valacyclovir: 1000 mg every 8 hours for 7 days
• Famciclovir: 500 mg three times daily for 7 days 1

Topical antibiotics may be used to prevent secondary bacterial infection from necrotic vesicles, as severe scarring can lead to cicatricial ectropion 1.

Important: Topical antivirals alone have not been shown helpful for VZV conjunctivitis but may be used as adjunctive treatment 1.

Key Clinical Pitfalls to Avoid

1. Do not use topical corticosteroids in HSV conjunctivitis—they worsen epithelial disease 1

2. Avoid prolonged trifluridine use (>2 weeks) due to inevitable epithelial toxicity 1

3. Monitor for SEIs starting 1+ weeks after onset—these affect quality of life through visual symptoms 1

4. Caution with systemic antivirals in renal impairment—dose adjustment needed 1

5. Recurrence risk: Patients with prior adenoviral infection may have SEI recurrence after photorefractive keratectomy or LASIK 1

Prevention and Infection Control

Hand hygiene is paramount—adenovirus survives on fomites for weeks and has a low infectious dose, facilitating rapid community spread 4, 3.

Herpes zoster vaccination is strongly recommended for patients ≥50 years and immunocompromised patients ≥19 years 1.